123 related articles for article (PubMed ID: 37907154)
1. Applying HDACis to increase SSTR2 expression and radiolabeled DOTA-TATE uptake: from cells to mice.
Klomp MJ; van den Brink L; van Koetsveld PM; de Ridder CMA; Stuurman DC; Löwik CWGM; Hofland LJ; Dalm SU
Life Sci; 2023 Dec; 334():122173. PubMed ID: 37907154
[TBL] [Abstract][Full Text] [Related]
2. Comparing the Effect of Multiple Histone Deacetylase Inhibitors on SSTR2 Expression and [
Klomp MJ; Dalm SU; van Koetsveld PM; Dogan F; de Jong M; Hofland LJ
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638389
[TBL] [Abstract][Full Text] [Related]
3.
Thakur S; Daley B; Millo C; Cochran C; Jacobson O; Lu H; Wang Z; Kiesewetter D; Chen X; Vasko V; Klubo-Gwiezdzinska J
Clin Cancer Res; 2021 Mar; 27(5):1399-1409. PubMed ID: 33355247
[TBL] [Abstract][Full Text] [Related]
4. Correlation of Somatostatin Receptor-2 Expression with Gallium-68-DOTA-TATE Uptake in Neuroblastoma Xenograft Models.
Zhang L; Vines DC; Scollard DA; McKee T; Komal T; Ganguly M; Do T; Wu B; Alexander N; Vali R; Shammas A; Besanger T; Baruchel S
Contrast Media Mol Imaging; 2017; 2017():9481276. PubMed ID: 29097943
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of [
Njotu FN; Ketchemen JP; Tikum AF; Babeker H; Gray BD; Pak KY; Uppalapati M; Fonge H
J Nucl Med; 2024 Apr; 65(4):533-539. PubMed ID: 38485273
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Ac-Lys
Dijkstra BM; de Jong M; Stroet MCM; Andreae F; Dulfer SE; Everts M; Kruijff S; Nonnekens J; den Dunnen WFA; Kruyt FAE; Groen RJM
J Neurooncol; 2021 Jun; 153(2):211-222. PubMed ID: 33768405
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic drugs in somatostatin type 2 receptor radionuclide theranostics and radiation transcriptomics in mouse pheochromocytoma models.
Ullrich M; Richter S; Liers J; Drukewitz S; Friedemann M; Kotzerke J; Ziegler CG; Nölting S; Kopka K; Pietzsch J
Theranostics; 2023; 13(1):278-294. PubMed ID: 36593963
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of [
Tafreshi NK; Pandya DN; Tichacek CJ; Budzevich MM; Wang Z; Reff JN; Engelman RW; Boulware DC; Chiappori AA; Strosberg JR; Ji H; Wadas TJ; El-Haddad G; Morse DL
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3408-3421. PubMed ID: 33772332
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
[TBL] [Abstract][Full Text] [Related]
10. The Effect of VPA Treatment on Radiolabeled DOTATATE Uptake: Differences Observed In Vitro and In Vivo.
Klomp MJ; Hofland LJ; van den Brink L; van Koetsveld PM; Dogan F; de Ridder CMA; Stuurman DC; Clahsen-van Groningen MC; de Jong M; Dalm SU
Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057069
[No Abstract] [Full Text] [Related]
11. Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of
Shah RG; Merlin MA; Adant S; Zine-Eddine F; Beauregard JM; Shah GM
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33435224
[TBL] [Abstract][Full Text] [Related]
12. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of copper-64-labeled somatostatin agonists and antagonist in SSTr2-transfected cell lines that are positive and negative for p53: implications for cancer therapy.
Nguyen K; Parry JJ; Rogers BE; Anderson CJ
Nucl Med Biol; 2012 Feb; 39(2):187-97. PubMed ID: 22056254
[TBL] [Abstract][Full Text] [Related]
14.
Liu F; Zhu H; Yu J; Han X; Xie Q; Liu T; Xia C; Li N; Yang Z
Tumour Biol; 2017 Jun; 39(6):1010428317705519. PubMed ID: 28618966
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, and Biological Evaluation of
Liu F; Liu T; Xu X; Guo X; Li N; Xiong C; Li C; Zhu H; Yang Z
Mol Pharm; 2018 Feb; 15(2):619-628. PubMed ID: 29278911
[TBL] [Abstract][Full Text] [Related]
16. Multimodal Imaging of 2-Cycle PRRT with
Albrecht J; Exner S; Grötzinger C; Prasad S; Konietschke F; Beindorff N; Kühl AA; Prasad V; Brenner W; Koziolek EJ
J Nucl Med; 2021 Mar; 62(3):393-398. PubMed ID: 32859703
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous Imaging of Ga-DOTA-TATE and Lu-DOTA-TATE in Murine Models of Neuroblastoma.
Zheng Y; Huh Y; Vetter K; Nasholm N; Gustafson C; Seo Y
IEEE Trans Radiat Plasma Med Sci; 2023 Jan; 7(1):75-82. PubMed ID: 37635919
[No Abstract] [Full Text] [Related]
18. SSTR-Mediated Imaging in Breast Cancer: Is There a Role for Radiolabeled Somatostatin Receptor Antagonists?
Dalm SU; Haeck J; Doeswijk GN; de Blois E; de Jong M; van Deurzen CHM
J Nucl Med; 2017 Oct; 58(10):1609-1614. PubMed ID: 28450563
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of a dual sstr2 and integrin α
Liu B; Zhang Z; Wang H; Yao S
Bioorg Med Chem; 2019 Nov; 27(21):115094. PubMed ID: 31540828
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of Somatostatin Receptor Type 2 Improves 177Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model.
Sharma R; Earla B; Baidoo KE; Zeiger MA; Madigan JP; Escorcia FE; Sadowski SM
Mol Cancer Ther; 2023 Sep; 22(9):1052-1062. PubMed ID: 37487000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]